Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-label, Three-Period Crossover Study to Investigate the Effect of a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tepotinib in Healthy Subjects

Trial Profile

Phase I, Open-label, Three-Period Crossover Study to Investigate the Effect of a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tepotinib in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Tepotinib (Primary) ; Omeprazole
  • Indications Liver cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 16 Jul 2018 Status changed from recruiting to completed.
    • 11 Jun 2018 Planned End Date changed from 3 Jul 2018 to 18 Jul 2018.
    • 11 Jun 2018 Planned primary completion date changed from 3 Jul 2018 to 29 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top